Portrazza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, advancements in monoclonal antibody development, expansion of oncology clinical infrastructure, rising use of targeted cancer drugs, improved cancer screening rates.

The growth in the forecast period can be attributed to increasing demand for precision oncology therapies, rising investments in biologic cancer drugs, expansion of egfr-targeted treatment pipelines, growing adoption of combination regimens, increasing focus on personalized lung cancer management. Major trends in the forecast period include increasing use of egfr-targeted monoclonal antibodies, rising adoption in lung cancer treatment protocols, growing focus on targeted oncology biologics, expansion of combination therapy approaches, enhanced emphasis on personalized cancer care.

The rising incidence of lung cancer is expected to drive the growth of the portrazza market in the future. Lung cancer is a type of cancer that originates in the lungs, typically in the cells lining the airways, and may spread to other parts of the body. Factors such as smoking, exposure to environmental pollutants, genetic factors, and occupational hazards like asbestos are contributing to the increasing incidence of lung cancer. Portrazza (necitumumab) targets and inhibits the epidermal growth factor receptor (EGFR), which is crucial in the growth and spread of cancer cells, thus slowing the progression of non-small cell lung cancer (NSCLC) when used in combination with chemotherapy. For example, the American Cancer Society's Facts and Figures report shows that the estimated number of new lung and bronchus cancer cases in the US rose from 236,740 in 2022 to 238,340 in 2023. As a result, the growing incidence of lung cancer is fueling the expansion of the portrazza market.

The increasing healthcare expenditure is expected to drive the growth of the portrazza market in the future. Healthcare expenditure refers to the total amount spent on healthcare services and products, including hospital care, physician services, prescription medications, and other medical goods and services. The rise in healthcare spending is driven by factors such as an aging population, a higher prevalence of chronic diseases, medical advancements, and increased demand for healthcare, all contributing to higher costs. Healthcare spending on Portrazza ensures its availability for patients needing treatment for advanced squamous non-small cell lung cancer. It also facilitates ongoing research, improved treatment protocols, and better patient outcomes through targeted therapy. For example, in April 2025, the Office for National Statistics, a UK-based government agency, reported that UK healthcare expenditure amounted to approximately US$414 billion (£317 billion) in 2024. Moreover, between 2023 and 2024, total healthcare expenditure increased by 6.5% in nominal terms. As such, the rising healthcare expenditure is supporting the growth of the portrazza market.

The trend towards personalized medicine is anticipated to further support the growth of the portrazza market. Personalized medicine refers to healthcare practices that customize medical decisions, treatments, and approaches based on a patient's genetic makeup and other personal factors. The movement towards personalized medicine is driven by advancements in genomics, biotechnology, and data analytics, which allow treatments to be tailored to individual genetic profiles. Portrazza (necitumumab) aligns with personalized medicine as it specifically targets the epidermal growth factor receptor (EGFR) to treat non-small cell lung cancer (NSCLC) with EGFR expression, offering a more personalized treatment based on the patient's unique biomarker profile. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant rise from the six approvals in 2022. Consequently, the shift towards personalized medicine is driving growth in the portrazza market.

Major companies operating in the portrazza market are Eli Lilly and Company.

North America was the largest region in the portrazza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the portrazza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the portrazza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the portrazza market by increasing costs of imported biologic drug substances, antibody production materials, sterile injectable packaging, and temperature-controlled logistics. Hospitals and oncology clinics in North America and Europe are most affected due to dependence on imported monoclonal antibody supplies, while Asia-Pacific faces higher distribution and procurement costs. These tariffs increase therapy expenses and strain oncology budgets. However, they are also encouraging regional biologics manufacturing, localized antibody production, and expanded domestic capabilities for oncology drug supply.

The portrazza market research report is one of a series of new reports that provides portrazza market statistics, including portrazza industry global market size, regional shares, competitors with a portrazza market share, detailed portrazza market segments, market trends and opportunities, and any further data you may need to thrive in the portrazza industry. This portrazza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Portrazza is a biologic drug containing necitumumab, a monoclonal antibody used for treating non-small cell lung cancer (NSCLC). It functions by targeting and inhibiting the epidermal growth factor receptor (EGFR), a protein involved in the growth and survival of cancer cells.

The primary indications for Portrazza include metastatic squamous NSCLC and locally advanced squamous NSCLC. Metastatic squamous NSCLC refers to the stage where cancer has spread to other parts of the body, and treatments focus on controlling its progression and improving the patient's quality of life. The drug is distributed through various channels such as direct sales, pharmaceutical wholesalers, and online pharmacies. Its end users include hospitals, oncology clinics, and home healthcare providers.

The portrazza market consists of sales of portrazza (necitumumab) injections, chemotherapy drugs, and supportive care drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.